PJP vs. IYH: Which Healthcare ETF Is the Better Buy?
This article compares two healthcare-focused exchange-traded funds (ETFs): the iShares U.S. Healthcare ETF (IYH) and the Invesco Pharmaceuticals ETF (PJP). IYH offers broad exposure to the healthcare sector with 100 holdings, a lower expense ratio of 0.38%, and a higher dividend yield, making it a more conservative choice. PJP is more concentrated with 29 stocks focused on drug development, has a higher expense ratio of 0.57%, and has recently outperformed due to strength in the pharmaceutical segment. Both funds share the same top three holdings—Eli Lilly, Johnson & Johnson, and AbbVie—but IYH is more top-heavy with these three comprising over 33% of assets. The article concludes that the choice depends on an investor's risk tolerance: PJP for those seeking concentrated pharma exposure and potential outsize gains, or IYH for steadier, lower-cost diversification.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection